The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
March 7th 2024
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Lack of Monitoring Among Older Patients With CML Linked to Poor TKI Adherence
January 8th 2022The findings showing that older patients with chronic myeloid leukemia (CML) had poor adherence to tyrosine kinase inhibitors (TKIs) was presented last month during the American Society of Hematology Meeting & Exposition.
Read More
Dr Steven Pergam Discusses NCCN's Preference for mRNA Vaccines
January 7th 2022Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, discusses the National Comprehensive Cancer Network's (NCCN) preference for mRNA vaccines and how they work differently.
Watch
ASH Posters Evaluate COVID-19 Risk Among Patients With Blood Cancers
December 24th 2021Research using data from the ASH Research Collaborative COVID-19 Registry for Hematology identified risk factors for severe infection and mortality for patients with blood cancers who were infected with COVID-19.
Read More
Third mRNA COVID-19 Vaccine Helps Some Patients With Blood Cancer Produce Antibodies for First Time
December 18th 2021There are 2 such vaccines now in use in the United States; the Pfizer-BioNTech vaccine is fully approved for the first 2 doses for those 16 and older, and the Moderna vaccine has an emergency use authorization for those 18 and older.
Read More
HRQOL Decreased During and Immediately After CAR T-Cell Therapy for DLBCL
November 16th 2021Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.
Read More
Tazemetostat Yields Fewer Safety Outcomes, Lower AE-Associated Costs vs PI3 Kinase Inhibitors
November 3rd 2021Two analyses presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting highlighted the safety and cost benefits of tazemetostat compared with phosphoinositide 3 (PI3) kinase inhibitors for patients with follicular lymphoma.
Read More
Comparing Costs and HRU for Tisagenlecleucel vs Axicabtagene Ciloleucel for DLBCL
October 25th 2021Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.
Read More
Dr Karen Winkfield on Taking Action to Address Disparities in Cancer
October 7th 2021There is a lot of evidence on the disparities in cancer care, but less on how to take those findings and turn them into actionable items to address the problem, said Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance.
Watch
Patient Characteristics Impact Effectiveness of TKIs in CML and AEs Experienced
October 1st 2021Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).
Read More
Second-Generation BTK Inhibitors Seek to Build Off Ibrutinib Success in CLL
September 29th 2021These second-generation inhibitors include acalabrutinib, zanubrutinib, and tirabrutinib, and researchers hope they can overcome the off-target toxicity and treatment resistance that can be experienced with ibrutinib.
Read More